2025 ESC/EACTS Valvular Heart Disease Guidelines — Quick Reference

What's New in 2025

The 2025 update introduces significant changes in valvular heart disease management, reflecting new clinical evidence and expanded interventional options:

Key New Recommendations

Aortic Stenosis: TAVI now Class IIb for severe aortic regurgitation in symptomatic patients ineligible for surgery; refined indications for asymptomatic severe AS intervention
Aortic Regurgitation: Expanded indications for intervention in symptomatic patients; surgical thresholds clarified (LVEDD >65 mm, LVESD >50 mm, LVEF <55%)
Mitral Regurgitation: Surgical repair Class I for low-risk symptomatic patients; TEER indications expanded with improved evidence
Tricuspid Regurgitation: New severity grading system introduced; emerging transcatheter options (TEER) Class IIb for high-risk patients
Prosthetic Valves: Updated antithrombotic management for mechanical and biological valves; refined bridging strategies
Multiple Valve Disease: Enhanced guidance on concomitant valve interventions and multi-modality assessment
Pregnancy & VHD: Sex-specific considerations expanded; preconception counseling emphasized

Pearl: Heart Team evaluation is essential for all complex valve cases. Shared decision-making with the patient regarding mode of intervention improves outcomes and patient satisfaction.

General Principles

The Heart Team and Heart Valve Centre

A multidisciplinary approach is critical for optimal outcomes. The Heart Valve Centre must include:

Core Team: Clinical cardiologist, cardiac surgeon, interventional cardiologist
Extended Team: Anesthesiologist, echocardiographer, cardiac imaging specialist
Support: Specialized nursing staff, data management, patient education

Institutional Requirements: 24/7 cardiac interventional capacity, multimodal imaging expertise (echo, CT, CMR, nuclear), high procedural volume, data registry, and ongoing education programs

Regional Networks

Integrated Heart Valve Networks coordinate outpatient clinics, procedural centers, and rehabilitation services, ensuring timely diagnosis, appropriate treatment, and long-term follow-up across healthcare systems.

Imaging Assessment

Multimodality Approach

Comprehensive evaluation requires integrated assessment with multiple imaging techniques:

Transthoracic Echo

First-line diagnostic tool. Assess valve morphology, dysfunction severity, cardiac chambers, hemodynamic burden.

Transesophageal Echo

Superior for surgical planning, intervention guidance, and assessment of complex anatomy.

Cardiac CT

Excellent for coronary artery disease, aortic root anatomy, leaflet calcification, and device sizing.

Cardiac MR

Ideal for chamber volumes, regurgitant fraction, myocardial fibrosis assessment.

Pitfall: Relying on single imaging modality can miss important diagnostic details. Integrated assessment is essential before intervention.

Risk Stratification

Surgical Risk Scoring

Multiple risk models are available to estimate perioperative mortality and morbidity. The most commonly used include:

EuroSCORE II: Systematic operative risk evaluation; incorporates patient, cardiac, and procedural factors
STS-PROM: Society of Thoracic Surgeons predicted risk of mortality; validated across surgical populations
TAVI-Specific Scores: Risk algorithms incorporating anatomic and clinical variables

Comorbidity Assessment

Evaluate frailty, renal dysfunction, pulmonary hypertension, and other organ system involvement to guide treatment modality selection (surgery vs. transcatheter vs. medical therapy).

Key Principle: Risk assessment should be individualized, incorporating quantitative scores, clinical judgment, and patient preferences. Heart Team discussion is essential for complex cases.

Aortic Stenosis

Severity Grading

Aortic stenosis severity is classified using a combination of hemodynamic parameters:

Parameter	Non-Severe	Moderate	Severe
Mean Gradient (mmHg)	<20	20-40	>40
Peak Velocity (m/s)	<3.0	3.0-4.0	>4.0
AVA (cm²)	>1.5	1.0-1.5	<1.0
AVAi (cm²/m²)	>0.9	0.6-0.9	<0.6

Low-Flow, Low-Gradient AS

Characterized by mean gradient <40 mmHg, AVA <1.0 cm², and SVI ≤35 mL/m². Dobutamine stress echocardiography or exercise testing can help distinguish true severe AS from pseudo-severe AS.

Indications for Intervention

Symptomatic Severe AS (Class I)

Dyspnea, syncope, angina, or exertional limitation
High-gradient AS (mean gradient ≥40 mmHg, Vmax ≥4.0 m/s)
Low-flow, low-gradient AS with LVEF ≤50%

Mode of Intervention Selection

Age <70 years with low surgical risk: SAVR (Class I)

Age ≥70 years with tricuspid AS and suitable anatomy: TAVI (Class I)

All remaining candidates: Heart Team assessment of individual characteristics. SAVR or TAVI recommended based on risk-benefit discussion with patient (Class I)

Prosthesis Selection

Biological Valve: Shorter lifespan but avoids lifelong anticoagulation. Preferred in older patients (>70 years) or those with contraindications to anticoagulation.

Mechanical Valve: Longer durability but requires lifelong vitamin K antagonist (INR 2-3 for aortic position). Preferred in younger patients with long life expectancy.

Aortic Regurgitation

Severity Assessment

Chronic aortic regurgitation severity incorporates qualitative, semi-quantitative, and quantitative parameters:

Severe AR Criteria:

Qualitative: Abnormal valve morphology, flail cusp, large coaptation defect
Semi-quantitative: Vena contracta >6 mm, PHT <200 ms, large central jet (≥65% LVOT), holodiastolic flow reversal in descending aorta
Quantitative: EROA ≥30 mm², RVol ≥60 mL/beat, RF >50%

Surgical Intervention Thresholds

Clinical Scenario	Surgical Threshold	COR
Symptomatic Severe AR	AV surgery recommended regardless of LVEF or LVEDD	I
Asymptomatic with LVEF ≤55%	AV surgery recommended	I
Asymptomatic with LVEDD >65 mm	AV surgery recommended	I
Asymptomatic with LVESD >50 mm	AV surgery considered	IIb
Preserved LV with LVEDD ≤65 mm	Watchful waiting; close monitoring	I

Acute Aortic Regurgitation

Acute severe AR (from endocarditis, aortic dissection, or trauma) requires urgent surgical intervention (Class I). Medical therapy provides temporary hemodynamic support but is not definitive.

Mitral Regurgitation

Primary vs. Secondary MR

Primary MR: Structural abnormality of mitral valve apparatus (flail leaflet, prolapse, myxomatous degeneration).

Secondary MR: Geometric distortion from LV dilatation, ischemia, or atrial remodeling with intact valve structure.

Severe MR Grading

Quantitative Criteria for Severe MR:

EROA: ≥40 mm²
Regurgitant Volume: ≥60 mL/beat
Regurgitant Fraction: ≥50%
Vena Contracta: ≥7 mm (≥8 mm biplane)

Primary MR - Surgical Indications

Symptomatic Severe PMR (Class I)

LVEF >60% AND (LVEDD ≥40 mm OR LVESi ≥20 mm/m²)
At least 3 of: AF, SPAP >50 mmHg, LA dilation ≥60 mL/m², Secondary TR ≥moderate
MV repair recommended (durability likely, experienced center)

MitraClip / Transcatheter Edge-to-Edge Repair (TEER)

Class IIb indication: Symptomatic severe PMR in patients who are high-risk or ineligible for surgery, with suitable anatomy. TEER is also considered for secondary MR not responding to optimal medical therapy.

Secondary MR

Management focuses on optimizing medical therapy (GDMT, CRT) and treating underlying LV dysfunction. TEER Class I: Severe secondary MR with HFrEF despite optimal GDMT.

Mitral Stenosis

Severity and Grading

Parameter	Mild	Moderate	Severe
Mean Gradient (mmHg)	<5	5-10	>10
MVA (cm²)	>1.5	1.0-1.5	<1.0
PHT (ms)	<40	40-60	>60

Percutaneous Mitral Balloon Valvuloplasty (PMBV)

PMBV Indications (Class I)

Symptomatic (NYHA II-IV) or asymptomatic with high thromboembolic risk
Mitral valve area ≤1.5 cm²
Favorable anatomy (Wilkins score ≤8, no LA thrombus, minimal MR)
No contraindications (severe calcification, extensive commissural fusion)

Surgical Options

Closed Commissurotomy: Limited role; considered for young patients with favorable anatomy at specialized centers.

Open Commissurotomy: Preferred for selected patients with favorable morphology and contraindications to PMBV.

Valve Replacement: Required for unfavorable anatomy, failed PMBV, or recurrent stenosis.

Tricuspid Regurgitation

New Severity Grading (2025)

Updated classification incorporates advanced imaging parameters:

Quantitative

EROA ≥40 mm², RVol ≥45 mL/beat, RF ≥50%, 3D VCA ≥75 mm²

Semi-Quantitative

PISA radius ≥9 mm, Vena contracta ≥7 mm, Hepatic vein systolic reversal

Qualitative

Flail leaflet, large coaptation defect, severe tenting

Mechanism Classification

Primary TR (6%): Rheumatic, endocarditis, congenital, carcinoid syndrome, trauma.

Secondary TR (94%): RV dilatation, RV dysfunction, pulmonary hypertension, AF, CIED-related.

Indications for Intervention

Surgical TR Intervention

Class I: Symptomatic severe primary/secondary TR; concomitant with left-sided valve surgery
Class IIb: High-risk patients ineligible for surgery; TEER considered if anatomy suitable

Pearl: Emerging transcatheter options (TEER) are expanding treatment possibilities for high-risk patients with severe TR. Results show improved quality of life and RV remodeling.

Management of Prosthetic Valves

Mechanical Heart Valves (MHV)

Valve Position	Target INR	Range
Aortic Position	2.5	2.0-3.0
Mitral Position	3.0	2.5-3.5
Tricuspid Position	3.0	2.5-3.5

Vitamin K Antagonist (VKA) Management

Initiation: Start UFH or LMWH within 24 hours of surgery until INR therapeutic
Target achievement: INR 2-3 for aortic; 2.5-3.5 for mitral/tricuspid
Patient education: INR self-monitoring improves efficacy and safety
Bridging: For non-cardiac surgery, interrupt VKA 3-4 days pre-operatively; bridge with LMWH

Bioprosthetic Valves (BHV)

Antithrombotic Strategy:

Lifelong OAC: If atrial fibrillation or thromboembolism risk factors present (Class I)
Aspirin 75-100 mg/day: If no AF and low thromboembolism risk (Class I)
VKA post-operatively: First 3 months (INR 2-3) to prevent thromboemboli

Durability and Reoperation

Structural valve deterioration risk increases with time. Younger patients have higher reintervention rates (~50% by 15 years). Reoperation options include redo SAVR, TAVI in failed bioprosthesis, or re-TAVI depending on anatomy.

Infective Endocarditis Prophylaxis

Indications for Antibiotic Prophylaxis

Prophylaxis is recommended for patients with established rheumatic heart disease history, complex congenital heart disease, prosthetic valves, and history of endocarditis.

Prophylactic Regimens

Standard Regimen:

Benzathine benzylpenicillin G: 1.2 million units IM every 3-4 weeks
Penicillin-allergic: Macrolide or cephalosporin
Duration: Long-term in high-risk groups with recurrent episodes

Key Do's

Educate patients on signs/symptoms of endocarditis (fever, malaise, new murmur)
Ensure adequate oral hygiene and dental care
Provide patient with endocarditis information card

Multiple and Mixed Valve Disease

Combined Aortic Stenosis + Aortic Regurgitation

Assessment of hemodynamic burden from both stenotic and regurgitant lesions is critical. Integrated approach with multimodality imaging guides intervention timing.

Mitral Stenosis + Mitral Regurgitation

Combination complicates gradient assessment. Mean gradient may be underestimated due to reduced flow. TOE and spectral Doppler help clarify severity.

Multiple Valve Disease

Indications for Intervention in Multiple VHD:

Simultaneous intervention: Preferred for multiple severe lesions with clear indications for each valve
Staged approach: May be necessary if only one valve meets clear intervention criteria
Heart Team decision: Individualized based on lesion severity, LV function, surgical risk

Pitfall: Underestimating secondary regurgitation. Comprehensive evaluation of all four valves is essential.

Valvular Heart Disease and Pregnancy

High-Risk Lesions

Severe aortic stenosis: High mortality risk; intervention before pregnancy recommended
Severe mitral stenosis: Increased hemodynamic burden; PMBV before pregnancy if feasible
Pulmonary hypertension: Extreme risk; pregnancy contraindicated
Cyanotic heart disease: High fetal loss, maternal mortality

Preconception Counseling

All women of childbearing age with VHD should receive risk stratification, discussion of intervention options before conception, anticoagulation management plans, and cardiovascular monitoring strategies.

Pregnancy Management

Essential Elements

Multi-disciplinary team (obstetrics, cardiology, anesthesia)
Close monitoring for symptoms and hemodynamic changes
Anticoagulation management (VKA risks in first trimester)
Activity modification and diuretic therapy as needed
Delivery planning (vaginal vs. cesarean, epidural vs. general anesthesia)

Noncardiac Surgery with Valvular Heart Disease

Preoperative Evaluation

Assess VHD severity, hemodynamic status, and planned surgical procedure to determine perioperative risk and need for intervention.

Antithrombotic Management

Valve Type	Bleeding Risk	Management
Mechanical Valve (MHV)	Low	Continue VKA (target INR); minor procedures proceed without interruption
MHV	High	Interrupt VKA 3-4 days pre-op; bridge with LMWH or UFH; resume VKA post-op
Biological Valve (BHV)	Any	Continue antiplatelet therapy if not AF; manage per bleeding risk

Pearl: Perioperative anticoagulation bridging is critical to prevent valve thrombosis in MHV patients. LMWH is preferred in most settings.

Clinical Do's and Don'ts

DO

Refer all complex VHD cases to a dedicated Heart Valve Centre for Heart Team evaluation
Use multimodality imaging (TTE, TOE, CCT, CMR) for comprehensive assessment before intervention
Perform objective risk stratification using validated scores (EuroSCORE II, STS-PROM) before intervention
Engage in shared decision-making with patients regarding mode of intervention (surgery vs. transcatheter)
Educate patients on symptom recognition and importance of long-term follow-up
Ensure lifelong monitoring of prosthetic valve function and anticoagulation status
Consider patient factors (age, life expectancy, lifestyle preferences) in prosthesis selection

DON'T

Delay intervention in symptomatic severe valve disease (AS, AR, MR) due to perceived surgical risk
Rely on single imaging modality (echo alone) for comprehensive valve assessment
Ignore comorbidities and frailty in perioperative risk stratification
Perform isolated TV surgery without comprehensive evaluation of left-sided valves
Neglect antithrombotic management in prosthetic valve recipients
Assume medical therapy alone will prevent progression in severe hemodynamically significant lesions
Underestimate secondary (atrial/ventricular) regurgitation when planning intervention
Forget to address endocarditis prophylaxis in high-risk patients

Clinical Calculators

The following calculators are available to assist with risk stratification, hemodynamic assessment, and clinical decision-making:

EuroSCORE II

Operative risk evaluation incorporating patient, cardiac, and procedural factors for surgical risk stratification.

Aortic Stenosis Severity

Classify AS as non-severe, moderate, or severe based on hemodynamic parameters (gradient, velocity, AVA).

Aortic Valve Calcium Score

Assess aortic valve calcification burden to aid in AS severity determination and risk stratification.

Projected AVA

Calculate projected aortic valve area at different heart rates for exercise assessment.

Gorlin Formula

Calculate mitral and aortic valve area using invasive hemodynamic data from cardiac catheterization.

Hakki Formula

Simplified method to estimate valve area without accurate heart rate or diastolic filling period.

Mitral Valve Area (PHT)

Calculate mitral valve area using the pressure half-time method from echocardiography.

E/e' Ratio

Estimate left ventricular filling pressures using transmitral and tissue Doppler parameters.

Left Atrial Volume Index

Calculate LAVI to assess left atrial size indexed to body surface area.

LV Mass Index

Calculate left ventricular mass indexed to body surface area for assessing LV hypertrophy.

CHA2DS2-VASc Score

Stroke risk assessment in atrial fibrillation to guide anticoagulation decisions.

HAS-BLED Score

Bleeding risk assessment in anticoagulated patients to balance thrombotic and hemorrhagic risk.

Adult GFR (MDRD)

Calculate estimated glomerular filtration rate for renal function assessment.

Creatinine Clearance

Estimate renal clearance using Cockcroft-Gault formula for medication dosing.

Corrected QT Interval

Correct QT interval for heart rate to assess QT prolongation risk during medication use.

Note: All calculators provide estimates based on standard formulas and published evidence. Clinical judgment and individualized patient assessment remain essential for treatment decisions.

References and Resources

Source: European Heart Journal. 2025;46:4635-4736. DOI: 10.1093/eurheartj/ehaf194

Authors: Fabien Praz (Chair), Michael A. Borger (Chair), and Task Force Members

Societies: European Society of Cardiology (ESC) & European Association for Cardio-Thoracic Surgery (EACTS)

Disclaimer: This quick reference summarizes key recommendations from the 2025 ESC/EACTS Valvular Heart Disease Guidelines. For comprehensive details, consult the full guideline text. Clinical decision-making should always involve multidisciplinary Heart Team discussion and individual patient consideration.